Share on StockTwits

Stock analysts at Morgan Stanley decreased their target price on shares of Chimerix (NASDAQ:CMRX) from $34.00 to $33.00 in a report issued on Monday. Morgan Stanley’s target price would suggest a potential upside of 37.90% from the stock’s previous close.

CMRX has been the subject of a number of other recent research reports. Analysts at Brean Capital initiated coverage on shares of Chimerix in a research note on Tuesday, July 8th. They set a “buy” rating and a $33.00 price target on the stock. Four analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and a consensus price target of $33.25.

Chimerix (NASDAQ:CMRX) opened at 23.93 on Monday. Chimerix has a 1-year low of $12.96 and a 1-year high of $27.69. The stock’s 50-day moving average is $22. and its 200-day moving average is $21.03. The company’s market cap is $853.6 million.

Chimerix (NASDAQ:CMRX) last announced its earnings results on Thursday, August 7th. The company reported ($0.39) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.44) by $0.05. Analysts expect that Chimerix will post $-1.64 EPS for the current fiscal year.

Chimerix, Inc is a biopharmaceutical company committed to the discovery, development and commercialization of novel, oral antiviral therapeutics that are designed to transform patient care in areas of high unmet medical need.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.